(Q43048199)

12 November 2017

A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. (English)

1 reference

12 November 2017

0 references

1 reference

3

1 reference

12 November 2017

4

1 reference

12 November 2017

5

1 reference

12 November 2017

Ralf Bartenschlager

7

0 references

author name string

Jan M Vrolijk

series ordinal

1

1 reference

PubMed ID

12798249

12 November 2017

Artur Kaul

series ordinal

2

1 reference

PubMed ID

12798249

12 November 2017

Solko W Schalm

series ordinal

6

1 reference

12 November 2017

1 June 2003

1 reference

Journal of Virological Methods

12 November 2017

1 reference

12 November 2017

110

1 reference

12 November 2017

2

1 reference

12 November 2017

201-209

1 reference

Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy

12 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900134-4

7 January 2021

Efficient initiation of HCV RNA replication in cell culture

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900134-4

7 January 2021

Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900134-4

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900134-4

7 January 2021

A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900134-4

7 January 2021

Effect of alpha interferon on the hepatitis C virus replicon

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900134-4

7 January 2021

Factors affecting the measurement of cytokines in biological fluids: implications for their clinical measurement

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900134-4

7 January 2021

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900134-4

7 January 2021

Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900134-4

7 January 2021

Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900134-4

7 January 2021

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900134-4

7 January 2021

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900134-4

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900134-4

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900134-4

7 January 2021

Biological assays for interferons

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900134-4

7 January 2021

Establishment of new and replacement World Health Organization International Biological Standards for human interferon alpha and omega

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900134-4

7 January 2021

Soluble interferon-alpha receptor molecules are present in body fluids

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900134-4

7 January 2021

Characterization of cell lines carrying self-replicating hepatitis C virus RNAs

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900134-4

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900134-4

7 January 2021

High sustained virological response in chronic hepatitis C by combining induction and prolonged maintenance therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900134-4

7 January 2021

10.1016/S0166-0934(03)00134-4

Identifiers

DOI

1 reference

12 November 2017

1 reference

PubMed ID

12798249